Premium
Down‐regulation of ASY/Nogo transcription associated with progression of adult T‐cell leukemia/lymphoma
Author(s) -
Shimakage Misuzu,
Inoue Nobumasa,
Ohshima Kohichi,
Kawahara Kunimitsu,
Oka Takashi,
Yasui Kazuta,
Matsumoto Kayoko,
Inoue Hirokazu,
Watari Akihiro,
Higashiyama Shinji,
Yutsudo Masuo
Publication year - 2006
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.22011
Subject(s) - leukemia , lymphoma , lung cancer , cancer research , adenocarcinoma , biology , gene expression , t cell leukemia , gene , cancer , immunology , medicine , pathology , genetics
Adult T‐cell leukemia/lymphoma (ATLL) is an aggressive form of human leukemia/lymphoma. Although this disease is initiated by infection with human T‐lymphotropic virus type 1 (HTLV‐1), many HTLV‐1 carriers survive for a long period without aggressive illness, suggesting that other factors may play roles in the progression of ATLL to an aggressive state. However, the mechanism involved in this progression still remains unclear. Previously, we have reported that ASY/Nogo mRNA was markedly down‐regulated in human small‐cell lung carcinomas, whereas it was expressed in normal tissues and other lung carcinomas, such as adenocarcinoma and squamous cell carcinoma. To understand whether or not ASY/Nogo gene is involved in the progression of ATLL, we examined the expression of ASY/Nogo mRNA in smoldering, chronic and aggressive ATLL, and found that the expression level of ASY/Nogo mRNA was markedly reduced in clinically aggressive ATLL. HTLV‐1 Tax expression was not affected by the down‐regulation of ASY/Nogo mRNA. These results indicate that the ASY/Nogo gene may act as a suppressor against ATLL progression, independent of Tax expression. © 2006 Wiley‐Liss, Inc.